This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2014 Aug;13(8):573.

doi: 10.1038/nrd4399.

Anticancer drugs: horizons broaden for PI3Kδ inhibitors

PMID: 25082283
DOI: 10.1038/nrd4399

Comment

Anticancer drugs: horizons broaden for PI3Kδ inhibitors

Katie Kingwell. Nat Rev Drug Discov. 2014 Aug.

. 2014 Aug;13(8):573.

doi: 10.1038/nrd4399.

Author

PMID: 25082283
DOI: 10.1038/nrd4399

No abstract available

PubMed Disclaimer

Comment on

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore CL, Hancox T, Maecker H, Friedman L, Turner M, Okkenhaug K, Vanhaesebroeck B. Ali K, et al. Nature. 2014 Jun 19;510(7505):407-411. doi: 10.1038/nature13444. Epub 2014 Jun 11. Nature. 2014. PMID: 24919154 Free PMC article.

References

1. Nature. 2014 Jun 19;510(7505):407-411 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- scite Smart Citations